ReNeuron Group PLC - Bridgend, Wales-based cell-based therapeutics firm - Reports "positive" data from Phase 2a trial of hRPC stem cell therapy candidate to treat retinitis pigmentosa, a disease which could lead to blindness. Says follow-up data has been gathered from patients six, nine, twelve and eighteen months after treatment. ReNeuron says a "clinically meaningful benefit" was seen on all time points.
Current stock price: 147.00 pence
Year-to-date change: down 1.3%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)